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Objectives: To evaluate the changes of peripheral lymphocyte subsets,
conventional drugs and remission rate in patients with systemic lupus
erythematosus (SLE) after immunomodulatory therapy.
Methods: A total of 89 patients with SLE from the Second Affiliated Hos-
pital of Shanxi Medical University from January 2016 to April 2018 were
enrolled, who were divided into well-controlled group and untargeted con-
trol group taking a full consideration of the patient‘s symptoms, signs and
related laboratory findings. We measured the absolute counts of B, NK,
CD8+T and helper T 1 (Th1), helper T 2 (Th2), helper T 17 (Th17) and
Treg cells in peripheral blood of patients before immunomodulatory ther-
apy and during the 3 months and 6 months of follow-up and 93 sex-
and age- matched control individuals using flow cytometry. Moreover, the
ratios of various cells to Treg cells were calculated.
Results: Compared with healthy controls, Treg cells in SLE patients were
significantly lower before the treatment with immunomodulator, while the
ratios of various pro-inflammatory lymphocytes to Treg cells (such as
Th2/Treg, Th17/Treg, CD8+T/Treg, etc.) were higher. After 3 months and
6 months with immunomodulatory therapy, the absolute number of Treg
cells in peripheral blood of SLE patients increased obviously reaching to
normal level. Accordingly, the ratios of various pro-inflammatory lympho-
cytes to Treg cells recovered. At the same time, the dose of glucocorti-
coid and disease-modifying antirheumatic drugs (DMARDs) decreased
distinctly. Additionally, the well-controlled group was able to maintain a
high remission rate, and the untargeted control group could achieve a
higher response rate after immunomodulatory treatment.
Conclusion: The imbalance between pro-inflammatory lymphocytes and
Treg cells caused by the significant decrease of Treg cells may be the
main cause of SLE. And immunomodulatory therapy we came up with
may reverse the imbalance of proinflammatory lymphocytes and Treg
cells, which is an potential and effective treatment for SLE.
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Background: Vitamin D deficiency is highly prevalent among patients with
systemic lupus erythematosus (SLE) [1]. Evidence from multiple studies
has shown that vitamin D deficiency in SLE is associated with a higher
disease activity [2]. There is conflicting evidence with regards to the rela-
tionship between fatigue and vitamin D level [3,4].
Objectives: The principal aim of this study was to establish any potential
effect on the level of fatigue, disease activity (measured by SLE disease
activity index-2K (SLEDAI-2K)) and interferon signature gene expression,
from vitamin D supplementation to SLE patients with vitamin D deficiency
or insufficiency.
Methods: 33 SLE patients, 13 with vitamin D deficiency and 20 with vita-
min D insufficiency, gave informed consent to participate in this 12 month
prospective study. Their participation consisted of an interview, filling of
the Fatigue Severity Scale (FSS), and blood tests. The patients were
advised to take vitamin D3 8000IU daily for 8 weeks if they were vitamin
D deficient, or 8000IU daily for 4 weeks if they were insufficient. This
was followed by 2000IU daily maintenance. The patients were re-
assessed after 6 and 12 months of vitamin D supplementation. RNA was
extracted from whole blood taken from the patients at baseline and after
6 months of vitamin D supplementation. The expression of 12 interferon
signature genes was measured in the extracted RNA by using Quanti-
Gene Plex technology. Approval to carry out this study was obtained
from the University Research Ethics Committee.
Results: 87.9% of SLE patients studied were female. The mean age was
47.6 years and the mean duration of SLE was 13.8 years. Table 1
shows the results obtained for several variables at baseline, after 6
months and after 12 months. The expression of all 12 interferon signa-
ture genes measured, was noted to decrease following 6 months of vita-
min D supplementation. This reached statistical significance for two of the
genes measured (OAS1, p=0.014; SOCS1, p=0.003).
Variable Time Mean Standard
Deviation
p-
value
SLEDAI-2K Baseline
6 months
12
months
3.97
3.36
2.61
3.359
2.924
2.193
0.210
0.009
Anti-dsDNA level (IU/mL) Baseline
6 months
12
months
210.31
194.08
190.50
234.416
214.129
208.131
0.032
0.030
Prednisolone daily dose
(mg)
Baseline
6 months
12
months
1.93
2.30
1.33
3.458
4.089
2.931
0.043
0.042
FSS Baseline
6 months
12
months
4.21
3.93
3.81
1.536
1.577
1.859
0.206
0.053
25-hydroxyvitamin D (ng/mL) Baseline
6 months
12
months
21.91
32.88
28.48
6.336
6.594
9.291
<0.001
0.001
Abstract AB0471 Table 1. Table showing results at baseline, after 6 months and after 12
months of vitamin D3 supplementation.
Conclusion: The results indicate that vitamin D supplementation in SLE
patients who are deficient or insufficient, results in an improvement in
disease activity, and possibly also in the level of fatigue. This could be
explained by the decrease in the expression of interferon signature
genes.
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